<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cytotoxic chemotherapy dose modification in patients with preexisting liver disease*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cytotoxic chemotherapy dose modification in patients with preexisting liver disease*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Cytotoxic chemotherapy dose modification in patients with preexisting liver disease*</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="22%"></colgroup><colgroup width="12%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Bilirubin</td> <td class="subtitle1">Aminotransferases</td> <td class="subtitle1">Percent dose administered</td> <td class="subtitle1">Reference</td> </tr> <tr class="divider_bottom"> <td>Bendamustine</td> <td>≥1.5 × ULN</td> <td>≥2.5 × ULN</td> <td>Not recommended</td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td>Bortezomib</td> <td>&gt;1.5 × ULN</td> <td> </td> <td>Reduce starting dose to 0.7 mg/m<sup>2</sup></td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td>Cabazitaxel</td> <td>&gt;ULN</td> <td>AST/ALT ≥1.5 × ULN</td> <td>0%</td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td>Carfilzomib</td> <td> </td> <td> </td> <td>Refer to text</td> <td class="centered"> </td> </tr> <tr> <td class="divider_bottom" rowspan="2">Cyclophosphamide</td> <td>3.1 to 5 mg/dL</td> <td>AST ≥180 IU/L</td> <td>75%</td> <td class="centered divider_bottom" rowspan="2">[1]</td> </tr> <tr class="divider_bottom"> <td>&gt;5 mg/dL</td> <td> </td> <td>0%</td> </tr> <tr class="divider_bottom"> <td>Cytarabine</td> <td> </td> <td>Any</td> <td>50%; subsequent increase by monitoring toxicity</td> <td class="centered">[1]</td> </tr> <tr class="divider_bottom"> <td>Dactinomycin</td> <td> </td> <td>Any</td> <td>50%; subsequent increase by monitoring toxicity</td> <td class="centered"> </td> </tr> <tr> <td class="divider_bottom" rowspan="3">Daunorubicin</td> <td>1.2 to 3 mg/dL</td> <td> </td> <td>75%</td> <td class="centered divider_bottom" rowspan="3">[1]</td> </tr> <tr> <td>3 to 5 mg/dL</td> <td> </td> <td>50%</td> </tr> <tr class="divider_bottom"> <td>&gt;5 mg/dL</td> <td> </td> <td>0%</td> </tr> <tr class="divider_bottom"> <td>Docetaxel</td> <td> </td> <td> </td> <td>Refer to text</td> <td class="centered"> </td> </tr> <tr> <td class="divider_bottom" rowspan="3">Doxorubicin</td> <td>1.2 to 3 mg/dL</td> <td>ALT or AST &gt;3 × ULN</td> <td>50%</td> <td class="centered divider_bottom" rowspan="3">[1]</td> </tr> <tr> <td>3 to 5 mg/dL</td> <td> </td> <td>25%</td> </tr> <tr class="divider_bottom"> <td>&gt;5 mg/dL</td> <td> </td> <td>0%</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Epirubicin</td> <td>1.2 to 3 mg/dL</td> <td>2 to 4 × ULN</td> <td>75%</td> <td class="centered divider_bottom" rowspan="2">[1]</td> </tr> <tr class="divider_bottom"> <td>&gt;3 mg/dL</td> <td>&gt;4 × ULN</td> <td>50%</td> </tr> <tr class="divider_bottom"> <td>Eribulin</td> <td> </td> <td> </td> <td>Refer to text</td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td>Etoposide</td> <td>1.5 to 3 mg/dL</td> <td>AST &gt;3 × ULN</td> <td>50%</td> <td class="centered">[1]</td> </tr> <tr class="divider_bottom"> <td>Fluorouracil</td> <td>&gt;5 mg/dL</td> <td> </td> <td>0%</td> <td class="centered">[1]</td> </tr> <tr class="divider_bottom"> <td>Gemcitabine</td> <td>&gt;1.6 mg/dL</td> <td> </td> <td>80%<sup>¶</sup></td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td>Ifosfamide</td> <td>&gt;3 mg/dL</td> <td> </td> <td>25%</td> <td class="centered">[1,2]</td> </tr> <tr class="divider_bottom"> <td>Irinotecan</td> <td>1.5 to 3 mg/dL</td> <td> </td> <td>75%</td> <td class="centered">[1]</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Ixabepilone monotherapy</td> <td>≤1 × ULN</td> <td>AST and ALT ≤2.5 × ULN</td> <td>Initial dose (40 mg/m<sup>2</sup>)</td> <td class="centered divider_bottom" rowspan="4"> </td> </tr> <tr> <td>≤1 × ULN</td> <td>AST and ALT ≤10 × ULN</td> <td>Initial dose (32 mg/m<sup>2</sup>)</td> </tr> <tr> <td>&gt;1.5 to ≤3 × ULN</td> <td>AST and ALT ≤10 × ULN</td> <td>Initial dose (20 to 30 mg/m<sup>2</sup>)</td> </tr> <tr class="divider_bottom"> <td>&gt;3 × ULN</td> <td>&gt;10 × ULN</td> <td>Not recommended</td> </tr> <tr class="divider_bottom"> <td>Ixabepilone plus capecitabine</td> <td>≥2.5 × ULN</td> <td>Above ULN</td> <td>Not recommended</td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td>Ixazomib</td> <td>&gt;1.5 × ULN</td> <td> </td> <td>Reduce starting dose to 3 mg</td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td>Paclitaxel</td> <td> </td> <td> </td> <td>Refer to text</td> <td class="centered"> </td> </tr> <tr> <td class="divider_bottom" rowspan="4">Panobinostat</td> <td>≥1 × ULN</td> <td>AST &gt;1 × ULN</td> <td>75%</td> <td class="centered divider_bottom" rowspan="4"> </td> </tr> <tr> <td>&gt;1 to 1.5 × ULN</td> <td>Any</td> <td>75%</td> </tr> <tr> <td>&gt;1.5 to 3 × ULN</td> <td>Any</td> <td>50%</td> </tr> <tr class="divider_bottom"> <td>&gt;3 × ULN</td> <td> </td> <td>Not recommended</td> </tr> <tr class="divider_bottom"> <td>Pomalidomide</td> <td> </td> <td> </td> <td>Refer to text</td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td>Procarbazine</td> <td>&gt;5 mg/dL</td> <td>ALT or AST &gt;3 × ULN</td> <td>0%</td> <td class="centered">[1]</td> </tr> <tr class="divider_bottom"> <td>Trabectedin</td> <td> </td> <td> </td> <td>Refer to text</td> <td class="centered"> </td> </tr> <tr class="divider_bottom"> <td>Vincristine, vinblastine</td> <td>&gt;3 mg/dL</td> <td> </td> <td>50%</td> <td class="centered">[3]</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Vinorelbine</td> <td>2.1 to 3 mg/dL</td> <td> </td> <td>50%</td> <td class="centered divider_bottom" rowspan="2">[1]</td> </tr> <tr class="divider_bottom"> <td>&gt;3 mg/dL</td> <td> </td> <td>25%</td> </tr> <tr> <td rowspan="2">Vorinostat</td> <td>&gt;1 to 3 × ULN</td> <td> </td> <td>Reduce initial dose<sup>Δ</sup></td> <td class="centered" rowspan="2"> </td> </tr> <tr> <td>&gt;3 × ULN</td> <td> </td> <td>Not recommended</td> </tr> </tbody></table></div><div class="graphic_footnotes">ULN: upper limit of normal; 
	AST: aspartate aminotransferase; 
	ALT: alanine aminotransferase;
	IU: international units.<br/>
	
	* Not an inclusive list.<br/>
	
	¶ Controversial. Supported by some studies<sup>[4]</sup>, but not others<sup>[5]</sup>.<br/>
	
	Δ US Food and Drug Administration (FDA) guidelines; Canadian guidelines recommend avoiding the drug for total bilirubin ≥1.5 × ULN.</div><div class="graphic_reference">References:
	<ol>
<li>Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33:50. </li>
<li>Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10:337. </li>
<li>Desai ZR, Van den Berg HW, Bridges JM, Shanks RG. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982; 8:211.</li>
<li>Venook A, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18:2780.</li>
<li>Teusink A, Hall PD. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother 2010; 44:750.</li>
</ol></div><div id="graphicVersion">Graphic 69104 Version 28.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
